îæ€çŽ¢
îæ€çŽ¢
î
BioLine RX Ltd
BLRXîãŠã©ãããªã¹ãã«è¿œå
3.285USD
0.0000.00%
çµå€Â 07/02, 13:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
14.29Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
詳现ãã£ãŒãã衚瀺
TradingKey åŸè¡šIntraday
1m
30m
1h
D
W
M
D
æ¬æ¥
0.00%
5æ¥é
+3.79%
1ã¶æ
-2.23%
6ã¶æ
+17.32%
幎åæ¥
+18.59%
1幎é
-26.84%
äž»èŠããŒã¿
3.220å§å€
3.285é«å€
5.06Kåºæ¥é«
æ倱é¡çŽè¿12ã¶æPER
æ倱é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
0.12%売買å転ç
3.170åæ¥çµå€
3.167å®å€
12.30K売買代é
æ倱é¡æ ªäŸ¡åçç
0.73PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-5.08%ç·è³ç£å©çç
7.77052é±é«å€
0.98åºæ¥é«æ¯ç%
-9.22MçŽå©ç
4.35Mæ ªåŒæ°
-0.49201æ ªåœããå©çïŒEPSïŒ
1.49ããŒã¿å€
-12.80%èªå·±è³æ¬å©çç
2.15052é±å®å€
3.72%æ¯ãå¹
79.38%ç²å©çç
14.29Mæ䟡ç·é¡
-1.49ãªã¹ã¯ãªã¿ãŒã³
3.78%ãªã¹ã¯ç
TradingKeyã®BioLine RX Ltdã®æ ªåŒã¹ã³ã¢î
é貚: USD æŽæ°æå»: 2026-07-02äž»èŠã€ã³ãµã€ã
BioLine RX Ltdã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå®å®ã§ããæé·ã®å¯èœæ§ã¯é¡èã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç 究æ¥çã§ã®é äœã¯387äž189äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯17.50ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããå瀟ã®æ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯éå»1ãæéã§å¹³åçã§ããããã¡ã³ãã¡ã³ã¿ã«ãºãšãã¯ãã«ã«ã¯åŒ±ãæ°Žæºã§ããæ ªäŸ¡ã¯æ¯æç·ãšæµæç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
BioLine RX Ltdã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ã¬ãŒããŒãã£ãŒã
çŸåš
ååå€
ã¡ãã£ã¢å ±é
éå»24æé
å ±éã¬ãã«
éåžžã«äœã
éåžžã«é«ã
äžç«
BioLine RX Ltdã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
æé·äž
å瀟ã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 1.18Mã«éããŠããŸãã
é©æ£æ°Žæº
å瀟ã®ææ°ã®PEã¯-6.68ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé©æ£åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯46.33Kæ ªã§ãåååææ¯ã§69.29%æžå°ããŠããŸãã
ã¢ããªã¹ãè©äŸ¡
1
人ã®ã¢ããªã¹ãäºæ³ã«åºã¥ã
è²·ã
çŸåšã®è©äŸ¡
17.500
ç®æšæ ªäŸ¡
+452.05%
äžæäœå°
BioLine RX Ltd ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
BioLine RX Ltdã®äŒæ¥æ å ±î
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
äŒæ¥ã³ãŒãBLRX
äŒæ¥åBioLine RX Ltd
æé«çµå¶è²¬ä»»è
ãCEOãSerlin (Philip Adam)
ãŠã§ããµã€ãhttps://www.biolinerx.com/
é¢é£éèåå
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%人æ°éæ
52852.900
+10.400Â (+0.02%)
29669.900
+358.500Â (+1.22%)
7507.800
+36.300Â (+0.49%)
14963.000
+160.000Â (+1.08%)
69676.000
+1528.000Â (+2.24%)
6412.400
+59.600Â (+0.94%)
68.683
+0.339Â (+0.50%)
308.630
+14.250Â (+4.84%)
194.830
-2.750Â (-1.39%)
4174.610
+52.700Â (+1.28%)
ãããã質å
BioLine RX LtdïŒBLRXïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îBioLine RX LtdïŒBLRXïŒã®çŸåšã®æ ªäŸ¡ã¯3.29ã§ãã
BioLine RX Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îBioLine RX Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯BLRXã§ãã
BioLine RX Ltdã®52é±é«å€ã¯ãããã§ããïŒ
îBioLine RX Ltdã®52é±é«å€ã¯7.77ã§ãã
BioLine RX Ltdã®52é±å®å€ã¯ãããã§ããïŒ
îBioLine RX Ltdã®52é±å®å€ã¯2.15ã§ãã
BioLine RX Ltdã®æ䟡ç·é¡ã¯ãããã§ããïŒ
îBioLine RX Ltdã®æ䟡ç·é¡ã¯14.29Mã§ãã
BioLine RX Ltd (BLRX) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãBioLine RX LtdïŒBLRXïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯17.50ã§ãã
BioLine RX Ltd (BLRX) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îBioLine RX LtdïŒBLRXïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.49ã§ãã